quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:59:27·31d
SECFiling
AbbVie Inc. logo

SEC Form DEF 14A filed by AbbVie Inc.

ABBV· AbbVie Inc.
Health Care
Full content unavailable. See the original source below.
Original source

Companies

  • ABBV
    AbbVie Inc.
    Health Care

Recent analyst ratings

  • Apr 21UpdateCanaccord Genuity$262.00
  • Feb 25UpdateRBC Capital Mkts$260.00
  • Feb 20UpdateBarclays$275.00
  • Jan 8UpdateWolfe Research-
  • Jan 7UpdateUBS$240.00
  • Dec 10UpdateHSBC Securities$265.00

Related

  • PR9h
    AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S.
  • PR1d
    AbbVie Selects North Carolina for New $1.4 Billion Manufacturing Campus
  • ANALYST2d
    Canaccord Genuity initiated coverage on AbbVie with a new price target
  • PR3d
    AbbVie and BioLabs Team Up to Support Life Sciences Innovation in Canada
  • PR9d
    Erin Lichy Gets Real About Her Natrelle® Breast Augmentation
  • PR10d
    Haisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for Pain
  • PR11d
    AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026
  • PR15d
    BOTOX® Cosmetic (onabotulinumtoxinA) Empowers Women Entrepreneurs Through "The Confidence Collective" for Fourth Year
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022